Saturday 17 October 2026 Export ALKS’s income statement to Excel — free account

Alkermes plc

ALKS Healthcare Drug Manufacturers Specialty & Generic

Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024. In the quarter to June 2026, revenue grew 27.0%, EPS fell 99.4% and free cash flow grew 1.13%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

41.22 1.12 +2.79%

Follow ALKS

Alert me

Market cap: $6.7B
P/E: 102×
Fwd P/E: −108×
Dividend yield: —
F-score: 7/9
Altman Z: 5.33
Beneish M: −3.29
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 10.28

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	2	2	2	4	2	3	3	2	4	2	1

Insider Ownership 2.55%

Capital & Financial Ratios $m

Market Cap 6,730.00

Revenue 1,667.65

Net Income 66.12

Free Cash Flow 222.71

Net Debt 846.53

Current Ratio 2.30

Debt/Equity 0.83

P/E ratio 102.28

Fwd P/E (108.00)

P/S ratio 4.13

P/B ratio 3.81

Past 5Y EPS Growth —

This Y EPS Growth (137.26%)

Next Y EPS Growth 200.38%

Next Y revenue growth 23.59%

Next 5Y EPS Growth (8.28%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 92.27%

10-year low 10-year high

P/S against its own 10 years 60.63%

10-year low 10-year high

P/B against its own 10 years 51.05%

10-year low 10-year high

EV/Sales against its own 10 years 68.56%

10-year low 10-year high

EV/FCF against its own 10 years 51.70%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	773	752	1,319	657
Receivables	332	385	334	456
Inventory	186	183	197	299
Other	95	5	—	—
	1,486	1,415	1,929	1,523

	2023	2024	2025	Q'26
Payables	241	185	290	332
ST’ Debt	3	—	—	27
Other	—	—	—	—
	520	465	543	662

Compound Annual Growth %

	10y	5y	3y
Sales	8.91%	7.28%	9.90%
Cash Flow	0.00%	44.44%	191.41%
Earnings	0.00%	0.00%	0.00%
Book Value	3.31%	11.26%	20.35%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	393	496	—	—	—
’25	307	391	394	385	1,476
’24	350	399	378	430	1,558
’23	288	617	381	377	1,663
’22	279	276	252	305	1,112
’21	251	304	294	324	1,174
’20	246	248	265	280	1,039

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(166)	145	—	—	—
’25	99	150	102	170	521
’24	21	146	82	190	439
’23	(21)	216	100	107	401
’22	22	(2)	1	1	21
’21	(45)	33	83	31	102
’20	(40)	(4)	60	67	83

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(170)	137	—	—	—
’25	90	136	84	171	481
’24	13	139	73	181	406
’23	(28)	206	85	91	354
’22	14	(12)	(10)	(9)	(17)
’21	(53)	26	78	22	73
’20	(60)	(15)	54	62	41

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.40)	0.00	—	—	—
’25	0.13	0.52	0.49	0.29	1.43
’24	0.21	0.53	0.55	0.88	2.17
’23	(0.25)	1.38	0.28	0.66	2.10
’22	(0.22)	(0.18)	(0.39)	(0.17)	(0.97)
’21	(0.14)	0.01	(0.18)	0.01	(0.30)
’20	(0.24)	(0.19)	0.00	(0.27)	(0.70)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	27.14	46.43	27.54	17.11	11.98	18.02	21.75	22.01	22.90	25.17	Analyst estimates 2026–2028 Powerpack
	High	78.88	63.40	71.22	37.75	22.22	33.00	32.79	33.71	32.88	36.45
People
People	Employees	1,750	2,000	2,300	2,235	2,245	2,211	2,280	2,100	1,800	2,050
	Revenue/emp, $m	0.43	0.45	0.48	0.52	0.46	0.53	0.49	0.79	0.87	0.72
Income, $m
Income, $m	Revenue	746	903	1,094	1,171	1,039	1,174	1,112	1,663	1,558	1,476
	Gross margin, %	82.28	82.87	83.88	84.59	82.83	83.19	80.39	84.79	84.25	86.69
	EBT	(214)	(143)	(127)	(197)	(97)	88	(31)	422	444	291
	EBT margin, %	(28.75)	(15.86)	(11.60)	(16.83)	(9.29)	7.47	(2.80)	25.34	28.49	19.75
	Net income	(208)	(158)	(139)	(197)	(111)	(48)	(158)	356	367	242
	Depreciation	94	99	104	80	82	79	78	75	29	27
Per share, $
Per share, $	Revenue	4.92	5.89	7.05	7.46	6.54	7.29	6.79	10.01	9.42	8.96
	Earnings	(1.38)	(1.03)	(0.90)	(1.25)	(0.70)	(0.30)	(0.97)	2.14	2.22	1.47
	Cash flow	(0.42)	0.13	0.64	0.46	0.52	0.63	0.13	2.41	2.66	3.16
	Capex	(0.29)	(0.33)	(0.44)	(0.57)	(0.26)	(0.18)	(0.23)	(0.29)	(0.20)	(0.24)
	Free cash flow	(0.71)	(0.21)	0.20	(0.11)	0.26	0.45	(0.11)	2.13	2.46	2.92
	Book value	7.98	7.84	7.55	6.91	6.72	6.91	6.37	7.24	8.86	11.05
	Shares, m	151	153	155	157	159	161	164	166	165	165
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	13.31	12.90	19.03
	P/S	11.40	9.38	4.18	2.74	3.05	3.19	3.81	2.86	3.05	3.12
	P/B	7.03	7.04	3.91	2.95	2.97	3.36	4.06	3.96	3.25	2.53
	EV/Sales	11.11	9.21	3.95	2.52	2.70	2.98	3.53	2.57	2.76	2.42
	EV/FCF	(77.24)	(260.41)	142.22	(163.99)	68.05	47.35	(227.81)	12.09	10.57	7.43
Cash, $m
Cash, $m	Operating cash flow	(64)	19	99	72	83	102	21	401	439	521
	Capex	(43)	(51)	(69)	(90)	(42)	(29)	(38)	(48)	(33)	(39)
	Free cash flow	(107)	(32)	30	(18)	41	73	(17)	354	406	481
Balance, $m
Balance, $m	Working capital	579	518	643	571	673	591	633	965	950	1,386
	Total debt	284	281	279	277	275	296	293	291	—	—
	Net debt	(214)	(152)	(260)	(258)	(360)	(241)	(315)	(483)	(752)	(1,319)
	Shareholders’ equity	1,209	1,203	1,171	1,085	1,067	1,113	1,044	1,203	1,465	1,819
Returns, %
Returns, %	ROA	(11.64)	(8.96)	(7.69)	(10.83)	(5.90)	(2.42)	(7.94)	17.35	17.51	10.64
	ROIC	(13.10)	(8.80)	(6.80)	(13.25)	(9.94)	7.01	(0.52)	35.95	36.86	31.75
	ROE	(16.52)	(13.10)	(11.74)	(17.43)	(10.30)	(4.42)	(14.68)	31.67	27.52	14.72

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ELAN Elanco Animal Health Incorporated	$11.8B	— (loss-making)	278×	+10.23% (above 0%: growing)	+450.00% (above 0%: growing)	+35.56% (above 0%: growing)	58.33%	7.97%	Compare
RDY Dr. Reddy's Laboratories Ltd	$10.7B	32.9×	24.3×	−14.44% (below 0%: shrinking)	−70.00% (below 0%: shrinking)	−143.40% (below 0%: shrinking)	46.54%	4.81%	Compare
HIMS Hims & Hers Health, Inc.	$6.9B	— (loss-making)	— (loss-making)	+38.25% (above 0%: growing)	n/m	+5.09% (above 0%: growing)	63.83%	(12.90%)	Compare
ALKS Alkermes plc	$6.7B	102×	— (loss-making)	+26.97% (above 0%: growing)	−99.43% (below 0%: shrinking)	+1.13% (above 0%: growing)	80.22%	3.70%
LNTH Lantheus Holdings, Inc.	$6.5B	23.7×	25.3×	+2.68% (above 0%: growing)	0.00%	+13.55% (above 0%: growing)	62.30%	25.82%	Compare
KNSA Kiniksa Pharmaceuticals International, plc	$6.2B	73.4×	38.7×	+55.36% (above 0%: growing)	+37.50% (above 0%: growing)	+66.63% (above 0%: growing)	90.32%	11.16%	Compare
AMRX AMNEAL PHARMACEUTICALS, INC.	$6.2B	38.4×	51.6×	+9.89% (above 0%: growing)	+157.14% (above 0%: growing)	−351.41% (below 0%: shrinking)	42.01%	16.30%	Compare
RGC Regencell Bioscience Holdings Limited	$4.7B	— (loss-making)	—	—	—	+57.15% (above 0%: growing)	0.00%	—	Compare
INDV Indivior Pharmaceuticals Inc.	$4.0B	11.2×	11.8×	+13.58% (above 0%: growing)	+580.00% (above 0%: growing)	+58.57% (above 0%: growing)	85.42%	46.36%	Compare
Median of peers	$6.4B	32.9×	32.0×	+10.23%	+97.32%	+24.56%	60.32%	11.16%

All 86 Drug Manufacturers Specialty & Generic stocks →

Alkermes plc (ALKS) key facts

Concern: Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024.
Alkermes plc (ALKS) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ALKS traded at $41.22, a market capitalization of $6.7 billion.
Return on equity was 14.7% and debt-to-equity 0.83.
Its Piotroski F-score is 7 out of 9 and its Altman Z-score is 5.33 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.